Impact of Phenotype on Recurrence of VT Post‐Ablation in Patients With Nonischemic Cardiomyopathy
Pacing and Clinical Electrophysiology · 2026-11 · 49 (11) · 1676-1684
DOI: 10.1111/pace.70340 ↗At a glance
Metaanalyse in Pacing and Clinical Electrophysiology, published online on 2026-06-26. Written by Shreyas Singireddy and 7 co-authors. Institution: Department of Cardiovascular Medicine, University of Illinois College of Medicine, Peoria, Illinois, USA. Major MEDLINE topics: Cardiomyopathies, Catheter Ablation, Tachycardia, Ventricular. 27 references.
Abstract (original language)
Background
Ventricular tachycardia (VT) ablation outcomes in nonischemic cardiomyopathy (NICM) may differ by disease phenotype, but prior studies have pooled NICM as a single entity. We performed a phenotype‐stratified meta‐analysis of VT ablation outcomes across six major NICM subtypes.
Methods
We systematically searched PubMed, Embase, and the Cochrane Library through January 2026. Studies were stratified by phenotype: lamin A/C (LMNA), cardiac sarcoidosis, dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), myocarditis, and arrhythmogenic right ventricular cardiomyopathy (ARVC). The primary outcome was VT recurrence. Proportions were pooled using restricted maximum likelihood estimation on the logit scale. Phenotype differences were tested via mixed‐effects meta‐regression.
Results
Eighteen studies (1699 patients) met inclusion criteria after rigorous center‐level overlap resolution. VT recurrence differed significantly across phenotypes (F [5,12] = 3.78, p = 0.027). LMNA had the highest recurrence (82.6%; 95% CI 51.6%–95.5%; k = 5), followed by sarcoidosis (57.1%; 32.2%–78.8%; k = 2), DCM (42.7%; 24.1%–63.6%; k = 4), HCM (36.2%; 23.8%–50.7%; k = 2), myocarditis (34.5%; 27.3%–42.5%; k = 2), and ARVC (33.8%; 16.0%–57.9%; k = 3). Phenotype explained 44.7% of between‐study heterogeneity.
Conclusions
VT ablation outcomes in NICM varied by the underlying disease phenotype, with recurrence rates ranging from 82.6% in LMNA cardiomyopathy to 33.8% in ARVC. These hypothesis‐generating findings argue against treating NICM as a unified category and provide a foundation for phenotype‐specific procedural counseling and clinical trial stratification that warrants validation in prospective registries.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Cardiovascular Medicine, University of Illinois College of Medicine, Peoria, Illinois, USA.
- Department of Internal Medicine, Piedmont Athens Regional Medical Center, Athens, Georgia, USA.
Cite
APA
Singireddy, S., Shoura, S., Venugopal, D., Chinnatambi, C., Shah, S., Sparrow, C., Baman, T., & Mehrotra, A. (2026). Impact of Phenotype on Recurrence of VT Post‐Ablation in Patients With Nonischemic Cardiomyopathy. Pacing and Clinical Electrophysiology, 49(11), 1676-1684. https://doi.org/10.1111/pace.70340
Vancouver
Singireddy S, Shoura S, Venugopal D, Chinnatambi C, Shah S, Sparrow C, et al. Impact of Phenotype on Recurrence of VT Post‐Ablation in Patients With Nonischemic Cardiomyopathy. Pacing and Clinical Electrophysiology. 2026;49(11):1676-1684. doi:10.1111/pace.70340
BibTeX
@article{Singireddy2026,
author = {Singireddy, Shreyas and Shoura, Sami and Venugopal, Darshine and Chinnatambi, Christopher and Shah, Siddharth and Sparrow, Christopher and Baman, Timir and Mehrotra, Amit},
title = {Impact of Phenotype on Recurrence of VT Post‐Ablation in Patients With Nonischemic Cardiomyopathy},
journal = {Pacing and Clinical Electrophysiology},
year = {2026},
volume = {49},
number = {11},
pages = {1676--1684},
doi = {10.1111/pace.70340}
}
EUVIMED